Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of CCK antagonists in Obstructive Sleep Apnea (OSA) syndrome
2013-004469-15Phase 2Completed
- Sponsor
- Rottapharm Biotech
- Start
- Nov 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of Dexloxiglumide and itriglumide in obstructive sleep apnea hypopnea syndrome (OSAHS) (2 arms), sponsored by Rottapharm Biotech. Primary endpoint: Apnea–Hypopnea Index (AHI) reduction. Started Nov 2013; status: completed.
02
Drugs
Dexloxiglumideitriglumide
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on 2013-004469-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004469-15.